The aim of this work was to assess the effects of pyrazinoylguanidine-type compared to benzoylguanidine-type NHE1 inhibitors or genetic ablation of NHE1, on growth, survival and sensitivity to anti-cancer therapy in various breast cancer subtypes grown as 3D spheroids. This evidence concerns the gene SLC9A1 and cancer.